Skip to main content

Advertisement

Table 3 Final values of plasma lipid, APOA1 and hepatic Apoa1 mRNA expression

From: Caloric restriction or telmisartan control dyslipidemia and nephropathy in obese diabetic Zücker rats

Animal NEFA (mg/dL) Cholesterol (mmol/L) HDL-c mmol/L Triglycerides (mg/dL) Plasma APOA1 (AU/L) Hepatic Apoa1(RAU)
Z 39.1 ± 8.2 7.4 ± 0.6 5.4 ± 0.4 365 ± 202 0.64 ± 0.03 ND
ZDFV 42.4 ± 20.0 7.2 ± 2.7 5.2 ± 1.9 1016 ± 654* 0.90 ± 0.1* 1.0 ± 0.4
ZDFT 37.4 ± 16.7 7.1 ± 3.2 5.6 ± 2.5 1086 ± 388* 0.78 ± 0.1 0.75 ± 0.2
ZDFD 44.2 ± 6.1 3.1 ± 0.6 2.4 ± 0.5 516 ± 240 0.80 ± 0.06* 0.7 ± 0.3
  1. Differences between non-diabetic and diabetic obese rats at the end of experimental interventions. Data are shown as mean ± SD. Statistically significant differences *p < 0.05 vs Zücker p < 0.05 vs ZDFV. Hyperlipidaemia in all groups was mainly due to elevated triglycerides with modest increases in total cholesterol, particularly HDL cholesterol levels, with the exception of the low-calorie diet group (ZDFD) in which cholesterol was significantly less than the others. Fatty-diabetic rats showed higher APOA1 plasma concentration and hepatic mRNA expression than fatty-diabetic rats that were on low-calorie diet (ZDFD) or telmisartan treatment (ZDFT).